Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with cystic fibrosis—an outcome William Blair found “potentially promising.”